Shionogi | The Epoch Times

Japanese Company Says New Oral COVID-19 Drug Ensitrelvir Achieves Primary Endpoint

Japanese pharmaceutical company Shionogi's new oral COVID-19 drug has achieved the primary endpoint in a clinical trial, the company announced in September. From February to July, Shionogi conducted a clinical ...

November 18, 2022BY Ellen Wan and Angela Bright

Japan’s Shionogi Says COVID-19 Pill Shows Rapid Clearance of Virus

TOKYO—An experimental treatment from Shionogi & Co. Ltd. has shown rapid clearance of the virus that causes COVID-19, ...

April 26, 2022BY Reuters

Japan-Based Shionogi’s COVID-19 Drug Associated With Birth Defects: Bloomberg

Shionogi & Co. stock slumped 16 percent in Tokyo after preclinical studies showed its experimental COVID-19 drug disturbed fetal ...

April 14, 2022BY Benzinga

Japan’s Shionogi Seeks Approval for COVID-19 Pill

TOKYO—Drugmaker Shionogi & Co. Ltd. has applied for approval to make and sell its oral COVID-19 treatment in ...

February 26, 2022BY Reuters

Japan’s Shionogi Starts Phase III Clinical Trial in Vietnam for COVID-19 Vaccine

TOKYO—Japan's Shionogi & Co. Ltd announced on Monday that phase III of its clinical trial for a new ...

December 27, 2021BY Reuters